Nammi Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.nammirx.com
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Ovarian CancerPancreas CancerUrothelial CarcinomaRenal Cell CarcinomaHepatocellular CarcinomaGastrointestinal CancerLung CancerProstate CancerBreast Cancer
- Interventions
- Biological: QXL138AM Injection every 2 weeks by IV Infusion
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-09-03
- Lead Sponsor
- Nammi Therapeutics Inc
- Target Recruit Count
- 100
- Registration Number
- NCT06582017
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport, California, United States
🇺🇸Sarah Cannon Research Institute - Denver DDU, Denver, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath